Forte Biosciences, Inc.
FBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $15 | $9 | $13 | $5 |
| G&A Expenses | $3 | $3 | $3 | $0 |
| SG&A Expenses | $3 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $18 | $12 | $16 | $7 |
| Operating Income | -$18 | -$12 | -$16 | -$7 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $0 | $0 | $0 |
| Pre-Tax Income | -$18 | -$11 | -$16 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$18 | -$11 | -$16 | -$7 |
| % Margin | – | – | – | – |
| EPS | -0.99 | -0.96 | -1.37 | -1.12 |
| % Growth | -3.1% | 29.9% | -22.3% | – |
| EPS Diluted | -0.99 | -0.96 | -1.37 | -1.12 |
| Weighted Avg Shares Out | 18 | 12 | 11 | 6 |
| Weighted Avg Shares Out Dil | 18 | 12 | 11 | 6 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$18 | -$12 | -$16 | -$7 |
| % Margin | – | – | – | – |